Identification of genetic markers with synergistic survival effect in cancer

BackgroundCancers are complex diseases arising from accumulated genetic mutations that disrupt intracellular signaling networks. While several predisposing genetic mutations have been found, these individual mutations account only for a small fraction of cancer incidence and mortality. With large-scale measurement technologies, such as single nucleotide polymorphism (SNP) microarrays, it is now possible to identify combinatorial effects that have significant impact on cancer patient survival.ResultsThe identification of synergetic functioning SNPs on genome-scale is a computationally daunting task and requires advanced algorithms. We introduce a novel algorithm, Geninter, to identify SNPs that have synergetic effect on survival of cancer patients. Using a large breast cancer cohort we generate a simulator that allows assessing reliability and accuracy of Geninter and logrank test, which is a standard statistical method to integrate genetic and survival data.ConclusionsOur results show that Geninter outperforms the logrank test and is able to identify SNP-pairs with synergetic impact on survival.

[1]  Jason H. Moore,et al.  BIOINFORMATICS REVIEW , 2005 .

[2]  Päivi Heikkilä,et al.  NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer , 2008, Nature Genetics.

[3]  M. Zweig,et al.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.

[4]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[5]  J. Lawless Statistical Models and Methods for Lifetime Data , 2002 .

[6]  Thilo Dörk,et al.  Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients , 2009, Breast Cancer Research.

[7]  Jerald F. Lawless,et al.  Statistical Models and Methods for Lifetime Data: Lawless/Statistical , 2002 .

[8]  W. Foulkes,et al.  Inherited susceptibility to common cancers. , 2008, The New England journal of medicine.

[9]  V. Bazan,et al.  Breast cancer genome-wide association studies: there is strength in numbers , 2012, Oncogene.

[10]  Deborah Hughes,et al.  Genome-wide association study identifies five new breast cancer susceptibility loci , 2010, Nature Genetics.

[11]  K Holli,et al.  Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2000, Journal of the National Cancer Institute.

[12]  Olivia Fletcher,et al.  Architecture of inherited susceptibility to common cancer , 2010, Nature Reviews Cancer.

[13]  K. Ovaska,et al.  Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme , 2010, Genome Medicine.

[14]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[15]  C. Daub,et al.  BMC Systems Biology , 2007 .

[16]  Laurent Briollais,et al.  SNP-SNP interactions in breast cancer susceptibility , 2006, BMC Cancer.

[17]  Timo Hakulinen,et al.  Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964–2003 followed up to the end of 2006 , 2010, Acta oncologica.

[18]  H. Nevanlinna,et al.  Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? , 2000, European journal of cancer.

[19]  Julie E Goodman,et al.  Association of breast cancer outcome with status of p53 and MDM2 SNP309. , 2006, Journal of the National Cancer Institute.

[20]  Anbupalam Thalamuthu,et al.  A combined analysis of genome-wide association studies in breast cancer , 2011, Breast Cancer Research and Treatment.

[21]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[22]  Timo Hakulinen,et al.  Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964–2003 followed up to the end of 2006 , 2010, Acta oncologica.

[23]  Scott M. Williams,et al.  challenges for genome-wide association studies , 2010 .

[24]  Päivi Heikkilä,et al.  Breast Cancer Patients with p53 Pro72 Homozygous Genotype Have a Poorer Survival , 2005, Clinical Cancer Research.

[25]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[26]  Päivi Heikkilä,et al.  Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients , 2005, International journal of cancer.

[27]  H. Cordell Detecting gene–gene interactions that underlie human diseases , 2009, Nature Reviews Genetics.